Electromotive intravesical delivery of mitomycin C (eMMC) has been proposed as a method to improve drug delivery across biological membranes and to increase drug accumulation in bladder tissue.

Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that ...

At that stage the surgeon may not be 100 per cent sure it's a cancer but if there's a strong suspicion a blue chemotherapy drug called Mitomycin C will be instilled into the bladder at the end of ...

UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for ...

Get detailed information on Mitomycin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Key inclusion criteria are as follows: Low grade NMIBC (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening. Negative voiding ...

UroGen Pharma (URGN) announced the presentation of the Phase 3 Envision trial’s efficacy and safety results at the Society of Urologic Oncology ...

Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling ...

These results, published online in the Journal of Urology in October, demonstrate that treatment with investigational therapy UGN-102, a mitomycin ... non-muscle-invasive bladder cancer (LG ...